Glioblastoma remains resistant to most conventional treatments. Emerging therapies aim to overcome the challenges posed by the blood–brain barrier and tumor microenvironment.
Recent clinical trials in glioblastoma have investigated a wide variety of therapeutic options, such as targeted agents, immunotherapies, and vaccine-based therapies. Find out more in this review.
Epilepsy due to primary or metastatic brain tumors accounts for 6–10% of all cases of epilepsy. Levetiracetam monotherapy is the initial treatment of choice, but other pharmacologic and nonpharmacologic options are also available.
CNS tumors are relatively rare in neonates and present differently than those occurring later in childhood in terms of etiology, clinical features, location, histology, and prognosis. How can neonatologists ensure early diagnosis and optimum treatment?
Our tailored content service will keep you up to date…
Receive newsletters curated for the busy specialist by our expert editorial team
Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.
A 68-year-old woman was admitted to the emergency department with headache, mental confusion, and a mild hemiparesis. Explore the imaging findings, differential diagnosis, and histopathological findings that revealed the patient’s diagnosis.
Intracranial GCTs developed occult extracranial malignancy with negative tumor markers, indicating that tumor marker monitoring may need to be combined with regular follow-up abdominal imaging for early detection.
A 77-year-old man developed rapid neurocognitive deterioration after resection, radiation, and chemotherapy for a glioblastoma and died suddenly. Lewy bodies in multiple subcortical regions indicates that treatment may have accelerated α-synuclein-induced neuronal damage.
Pediatric optic pathway/hypothalamic gliomas (OPHG) pose challenges in treatment due to their location and proximity to vital structures. Surgical resection plays a key role in the management of OPHG especially when the tumor exhibits mass effect …
Immunotherapy for glioblastoma (GBM) remains an intensive area of investigation. Given the seismic impact of cancer immunotherapy across a range of malignancies, there is optimism that harnessing the power of immunity will influence GBM as well.
Central nervous system (CNS) tumors are the most frequent solid tumors in children, making CNS tumors the leading cause of cancer-related death in children. Beyond CNS tumors, pediatric-type low-grade gliomas (pLGG) are the most frequent childhood …
Pediatric-type diffuse high-grade gliomas comprise 15–20% of all childhood central nervous system malignancies and are the leading cause of cancer-related death in children and adolescents [ 1 , 2 ]. Within this devastating spectrum of disease …
An expert-led symposium exploring the most pertinent issues in cardio-oncology, with a focus on the new ESC guidelines. Highlights include preventative approaches in cardio-oncology, toxicity risk-stratification strategies, the clinical management of myocarditis as an adverse effect of immune checkpoint inhibitor-treatments, and the utility of biomarkers in long-term follow-up of cardiovascular disease risk in cancer patients.
Medulloblastoma (MB) is the most common brain malignancy in pediatric patients, which accounts for 20–25% of pediatric central nervous system neoplasms [ 1 , 2 ]. Despite the increase in survival rates in recent years, prognosis of MB patients …
Glioblastoma (GBM) is the most aggressive glioma recurring on a regular basis despite extensive tumor treatment and usually resulting into a limited overall survival (OS) [ 1 ]. Although GBM is a clearly defined entity on a histological and …
Pediatric low-grade gliomas (pLGG) are the most common primary brain tumors in children [ 1 ]. They are a diverse group of WHO grade 1 and grade 2 glial and glioneuronal tumors [ 2 ], which typically contain a high proportion of tumor …
Glioblastoma multiforme (GBM) acquires resistance to bevacizumab (Bev) treatment. Bev affects angiogenic factors other than vascular endothelial growth factor (VEGF), which are poorly understood. We investigated changes in angiogenic factors under …
